The evolution of MRD-guided therapy for leukemia
Richard Dillon, MBBS, from King's College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML). The evolution of MRD-guided therapies is timel...
Author: VJHemOnc
Added: 07/24/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts